Detalles de la búsqueda
1.
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Oncologist
; 26(5): e749-e755, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33486783
2.
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Oncologist
; 25(3): e439-e450, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162822
3.
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Breast Cancer Res Treat
; 184(1): 23-35, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32783178
4.
Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Oncologist
; 24(12): 1514-1525, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31217344
5.
Palbociclib and Letrozole in Advanced Breast Cancer.
N Engl J Med
; 375(20): 1925-1936, 2016 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-27959613
6.
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Anticancer Drugs
; 29(3): 271-280, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29360661
7.
Separating the Siamese twins: using a π-shifted Sagnac interferometer to control the relative weight/influence of circular and linear birefringence on the loop transmission facilitating their measurement.
Opt Lett
; 42(5): 943-946, 2017 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28248337
8.
Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
Cell Biochem Funct
; 33(5): 334-40, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26178811
9.
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
J Clin Oncol
; 42(9): 994-1000, 2024 Mar 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38252901
10.
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
J Clin Oncol
; : JCO2301940, 2024 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38513188
11.
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Cancer
; 119(14): 2639-44, 2013 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23589078
12.
Control of late apoptotic events by the p38 stress kinase in L-glutamine-deprived mouse hybridoma cells.
Cell Biochem Funct
; 31(5): 417-26, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23080342
13.
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
J Clin Oncol
; 41(33): 5118-5130, 2023 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37556775
14.
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Oncologist
; 17(2): 260-6, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22285963
15.
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
Invest New Drugs
; 30(1): 266-72, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20697774
16.
Investigation of a cyanine dye assay for the evaluation of the biocompatibility of magnesium alloys by direct and indirect methods.
Bioact Mater
; 5(1): 26-33, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31956733
17.
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer.
Clin Cancer Res
; 26(1): 110-121, 2020 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31527167
18.
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Clin Breast Cancer
; 20(2): e173-e180, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31836434
19.
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.
JNCI Cancer Spectr
; 4(1): pkz085, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32337496
20.
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
J Natl Cancer Inst
; 111(4): 419-430, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30032196